Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines

Published:2024-06-12 Issue:4 Volume:4 Page:
ISSN:2752-4191
Container-title:European Heart Journal Open
language:en
Short-container-title:

Author:

Ketelhuth Daniel F J¹²³^ORCID,Bäck Magnus¹³⁴⁵^ORCID

Affiliation:

1. CArdiovascularREsolution of INflammation to promote HEALTH (CARE-IN-HEALTH) Consortium

2. Cardiovascular and Renal Research Unit, Department of Molecular Medicine, University of Southern Denmark , Campusvej 55, 5230 Odense , Denmark

3. Center for Molecular Medicine, Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm , Sweden

4. Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17164 Stockholm , Sweden

5. Nancy University Hospital, University of Lorraine and INSERM U1116 , Nancy , France

Funder

CARE-IN-HEALTH

European Union’s Horizon Europe Research and Innovation Framework programme for Health

European Union

European Health and Digital Executive Agency

D.F.J.K.

Novo Nordisk Foundation

Independent Research Fund Denmark

Simon Fougner Hartmanns Familiefond

University of Southern Denmark

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ehjopen/advance-article-pdf/doi/10.1093/ehjopen/oeae047/58208009/oeae047.pdf

Reference6 articles.

1. Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation;Knopp;Eur Heart J Open,2024

2. The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events;Maierean;Eur Heart J Open,2022

3. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial;Svensson;JAMA Cardiol,2022

4. Obesity-induced inflammation exacerbates clonal hematopoiesis;Pasupuleti;J Clin Invest,2023

5. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial;Ridker;Lancet,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3